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Abstract.
Background: In postmortem analysis of late stage Parkinson’s disease (PD) neuronal loss in the substantial nigra (SN)
correlates with the antemortem severity of bradykinesia and rigidity, but not tremor.
Objective: To investigate the relationship between midbrain nuclei volume as an in vivo biomarker for surviving neurons in
mild-to-moderate patients using 7.0 Tesla MRI.
Methods: We performed ultra-high resolution quantitative susceptibility mapping (QSM) on the midbrain in 32 PD partici-
pants with less than 10 years duration and 8 healthy controls. Following blinded manual segmentation, the individual volumes
of the SN, subthalamic nucleus, and red nucleus were measured. We then determined the associations between the midbrain
nuclei and clinical metrics (age, disease duration, MDS-UPDRS motor score, and subscores for bradykinesia/rigidity, tremor,
and postural instability/gait difficulty).
Results: We found that smaller SN correlated with longer disease duration (r = –0.49, p = 0.004), more severe MDS-UPDRS
motor score (r = –0.42, p = 0.016), and more severe bradykinesia-rigidity subscore (r = –0.47, p = 0.007), but not tremor or
postural instability/gait difficulty subscores. In a hemi-body analysis, bradykinesia-rigidity severity only correlated with SN
contralateral to the less-affected hemi-body, and not contralateral to the more-affected hemi-body, possibly reflecting the
greatest change in dopamine neuron loss early in disease. Multivariate generalized estimating equation model confirmed that
bradykinesia-rigidity severity, age, and disease duration, but not tremor severity, predicted SN volume.
Conclusions: In mild-to-moderate PD, SN volume relates to motor manifestations in a motor domain-specific and laterality-
dependent manner. Non-invasive in vivo 7.0 Tesla QSM may serve as a biomarker in longitudinal studies of SN atrophy and
in studies of people at risk for developing PD.
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INTRODUCTION
The hallmark pathological feature of Parkinson’s
disease (PD) is Lewy body formation in the substan-
tia nigra (SN) with progressive loss of dopaminergic
neurons. Early clinicopathological studies correlated
the number of surviving dopamine neurons at autopsy
with PD clinical symptoms prior to death, including
disease duration [1, 2] and severity of bradykine-
sia and rigidity [3–6]; however, these studies found
no relationship between surviving dopamine neurons
and tremor severity. These autopsy studies led to
the hypothesis that unlike bradykinesia and rigid-
ity, tremor is not primarily driven by dopaminergic
neuronal loss. This dichotomy resonates with clinical
studies as well; while dopamine replacement dramat-
ically improves bradykinesia and rigidity, many PD
patients experience dopamine-refractory tremor [7].
However, the autopsy studies underlying these
hypotheses are limited to the latest stages of dis-
ease, typically 15 to 20 years after symptom onset
when patients are older and more likely to have
developed severe bradykinesia and rigidity [1, 8].
Therefore, it is unknown if these clinicopathologi-
cal relationships exist in early PD. One alternative is
to study brain atrophy via magnetic resonance imag-
ing (MRI) in earlier patients with milder symptoms.
However, it is difficult to connect MRI signal with
surviving dopaminergic neurons in SN that diminish
with PD progression. Conventional MRI has diffi-
culties in resolving the boundaries between the SN
and surrounding tissue, including the subthalamic
nucleus (STN), prohibiting accurate volumetric mea-
surements [9].
Iron as a cofactor for dopamine generation is
omnipresent in functional neurons and is removed
after neuronal death, making iron a candidate
biomarker for surviving neurons in SN [10, 11]. As
iron is highly paramagnetic, SN can be detected on
MRI methods that are sensitive to tissue magnetic
susceptibility. Ultra-high field MRI suits well for
this task, because two features of MRI that improve
resolution scale approximately linearly with field
strength: (1) the signal-to-noise ratio [12] and (2)
the sensitivity to magnetic susceptibility [13, 14].
Many nuclei in the upper brainstem and midbrain
[STN, red nucleus (RN), and portions of the SN] con-
tain substantial iron [10] and are well visualized by
susceptibility-based contrasts such as T2*-weighted
imaging, R2* quantification, and quantitative sus-
ceptibility mapping (QSM) [15–21]. The higher
signal-to-noise ratio combined with the enhanced
iron-based contrast enables the probing of micro-
scopic anatomy with high resolution volumetric MRI
at 7.0 Tesla (7T) [22]. In particular, QSM, known to
be superior to R2* for mapping SN iron [23–27],
shows better interrater reliability for SN volumet-
ric tracing [28], and produces superb depictions of
iron-containing structures at 7T [29, 30].
Recent 7T MRI work has shown the promise for
resolving midbrain nuclei in movement disorders,
demonstrating disease-associated alterations in SN
volume, signal characteristics, and morphology rela-
tive to healthy controls [31–33]. While several studies
demonstrate a distorted SN with atrophied nigro-
somes in PD [9, 34–37], one T2*-weighted imaging
study at 7T found SN volume increased in PD [38].
However, SN volume measured on R2* or T2*-
weighted imaging suffers from blooming artifacts
that are highly dependent on imaging parameters
and object orientation [39]. QSM can be used to
minimize these blooming artifacts [39–42] and is
therefore an ideal MRI technique for SN volumetric
quantification.
There is considerable interest in using MRI meth-
ods to visualize and quantify midbrain nuclei as a
surrogate to dopamine neuron cell death in PD clini-
cal trials [43, 44]; however, the relationship of the SN,
STN, and RN to specific measures of bradykinesia,
rigidity, and tremor is not clear. Therefore, this study
aimed to (1) measure the volumes of midbrain nuclei
in patients with PD with QSM using ultra-high field
MRI (2) quantify QSM and R2* values for each of the
midbrain nuclei and, (3) determine if there is a selec-
tive relationship between midbrain nuclei volumes,




We recruited 32 participants with idiopathic PD
from the Stanford Movement Disorders Clinic and
the surrounding community. Inclusion criteria were
as follows: (1) age between 45 and 90 years, (2)
diagnosis of PD by a board-certified neurologist with
specialty training in movement disorders based on
Parkinson’s UK Brain Bank criteria [45], (3) a diag-
nosis of PD for less than 10 years, (4) a ≥ 30%
improvement in Movement Disorders Society Uni-
fied Parkinson’s disease Rating Scale, part III motor
exam (MDS-UPDRS-III) [46] when taking dopamin-
ergic medications [47], and (5) no history of other
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significant neurological disease, major psychiatric ill-
ness, substance abuse, or head trauma with loss of
consciousness more than 5 minutes. We also recruited
8 healthy control older adults, who showed no signs of
parkinsonism on comprehensive neurological exam.
All participants provided written informed consent to
participate in the study following protocols approved
by the Stanford Institutional Review Board.
Each participant underwent a clinical evaluation
that included a history, physical examination, and
neurological examination by a Movement Disorders
trained physician, who was blinded to the MRI data.
To identify specific motor manifestations related to
different midbrain nuclei volumes, three motor sub-
scores were calculated according to published criteria
[48]: the Bradykinesia-Rigidity Subscore (MDS-
UPDRS items 3.3, 3.4, 3.5, 3.6, 3.7, and 3.8), the
Tremor Subscore (MDS-UPDRS items 2.10, 3.15,
3.16, 3.17, and 3.18), and the Postural Instability/Gait
Difficulty (PIGD) Subscore (MDS-UPDRS items
2.12, 2.13, 3.10, 3.11, and 3.12). MDS-UPDRS part
II was unavailable from three participants, who were
thus excluded from the PIGD and Tremor Subscore
analysis since both of these Subscores require at least
one item from part II.
PD typically begins with unilateral limb symptoms
and progresses asymmetrically. Therefore, we calcu-
lated the hemi-body Subscores from the right and left
appendicular items of the MDS-UPDRS-III. For each
participant, a More-Affected side was determined
based on the higher overall hemi-body Subscore.
The More-Affected and Less-Affected hemi-body
Bradykinesia-Rigidity and Tremor Subscores were
then calculated. Because the PIGD Subscore contains
only axial items, this was not included the hemi-body
analysis.
MRI acquisition and processing
Scans were acquired using a GE 7T Discovery
950 whole-body MRI scanner (GE Healthcare,
Chicago, Illinois) with a 32-channel receive head
coil contained within a quadrature transmit coil
(Nova Medical Inc., Wilmington, Massachusetts).
Each scanning session began with a 3-plane localizer
scan, high-order shimming, and two short gradient
echo sequences to derive a complex coil sensitivity
profile. An axial three dimensional multi-echo
gradient echo scan was acquired using a suscep-
tibility weighted angiography (SWAN) sequence
centered on the midbrain covering approximately
the mid-pons to the mid-caudate, field of view
of 240 × 168 × 57.6 mm, acquisition matrix of
400 × 280 × 96 (reconstructed to 512 × 358 × 94),
acquisition resolution of 0.6 × 0.6 × 0.6 mm (recon-
structed to 0.47 × 0.47 × 0.6 mm), echo times
of 8/14/20/26/32 ms, repetition time = 32.5 ms,
flip angle = 12◦, receive bandwidth of +/-
62.5 kHz, acquisition time of 10 minutes 16
seconds. Additionally, a whole-brain coronal
magnetization-prepared fluid-attenuated inver-
sion recovery (MP-FLAIR) scan was obtained,
field of view of 179 × 179 × 173 mm, acqui-
sition matrix = 224 × 224 × 216 (reconstructed
to 256 × 256 × 216), acquisition resolution
of 0.8 × 0.8 × 0.8 mm (reconstructed to 0.7 ×
0.7 × 0.8 mm), echo time = 110 ms, repetition
time = 8000 ms, inversion time = 2135 ms, band-
width = 62.5 Hz/pixel, acquisition time of 5 minutes
24 seconds [49].
The magnitude images from the multi-echo gra-
dient echo acquisition were averaged across echo
times as an online reconstruction. Additionally,
the raw data from this acquisition was recon-
structed offline for each receiver coil, then combined
into complex images while preserving signal phase
using the complex coil sensitivity profiles [50].
Subject-specific binary masks were creating using
ITK-SNAP (http://www.itksnap.org) [51], and QSM
were generated from the complex images using
morphology-enabled dipole inversion [52]. R2* maps
were generated by log transformation followed by
linear fitting. The Functional Magnetic Resonance
Imaging of the Brain Software Library (FSL, version
5.0, fsl.fmrib.ox.ac.uk) [53] linear registration tool
was used to coregister the magnitude images from the
QSM acquisitions with the FLAIR images from each
participant, interpolating both to an isotropic voxel
size of 0.3 mm. Images were both automatically and
visually checked in a blinded manner for adequate
quality throughout the stages of preprocessing.
Segmentation of midbrain nuclei
Segmentation was performed by a single rater,
who was blinded to all clinical data. The SN, STN,
and RN were manually segmented in 3 dimensions
on the coregistered QSM and MP-FLAIR images
using ITK-SNAP. The primary segmentation was
performed in the coronal plane (Fig. 1). All three
structures were typically bright in the QSM images
(because of their iron content) facilitating direct visu-
alization, and dark in the MP-FLAIR images. The RN
was identified as an approximately spherical structure
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Fig. 1. Midbrain Nuclei Segmentation. Coronal images of the subthalamic nucleus, substantia nigra, and red nucleus on multi-echo gradient
echo (mGRE), quantitative susceptibility maps (QSM), and fluid-attenuated inversion recovery (FLAIR) images. Note the clear separation
of the substantia nigra from the subthalamic nucleus on the anterior images.
in the posterior midbrain. The SN was identified
posteriorly as an obliquely oriented linear structure
inferolateral to the RN and elliptical in the coronal
plane. The STN was itself also identified as being
elliptical in shape, immediately adjacent and superior
to the SN in the coronal plane, but generally separa-
ble in the QSM images from the SN by differences
in intensity and by comparison with the correspond-
ing MP-FLAIR images. For coronal slices in which
SN-STN boundary was unclear, the nearest coronal
slice in which it was clear was used as a guide. After
segmenting in the coronal plane, segmentations were
adjusted in the axial plane to ensure smoothness and
contiguity.
After the initial segmentation was performed, two
additional blinded raters experienced in brain seg-
mentation checked the segmentation and provided
additional suggestions for editing, which was then
judged as adequate by a final consensus. Finally,
to validate reproducibility of our segmentation tech-
nique, a second rater, who was also blinded to all
clinical data, performed a separate segmentation on a
subset of 12 participants with an inter-rater reliability
of 0.973 for the SN, 0.970 for the STN, and 0.839 for
the RN using the Intraclass Correlation Coefficient,
two-way mixed for absolute agreement.
We calculated the volume of each right and left
STN, SN, and RN separately in mm3. We then
extracted the mean QSM and R2* values for each
of the nuclei volumes. QSM values were normalized
by subtracting from the mean susceptibility within a
3rd ventricular cerebrospinal fluid region of interest.
Statistical analysis
Analyses were conducted in two stages, focused
principally on the PD cohort. In the first stage
we conducted a series of bivariate analyses using
Spearman rho correlation coefficients to broadly
assess the relationship between each of the midbrain
nuclei and clinical metrics (age, disease duration,
MDS-UPDRS-III total, and subscores for bradyki-
nesia/rigidity, tremor, and PIGD). Scatterplots were
generated for significant correlations. For analyses
of global measures of disease, such as duration, we
averaged the right and left sides for each of the three
nuclei. Because PD pathology is asymmetric, we ana-
lyzed lateralized measures (the bradykinesia/rigidity
subscore and the tremor subscore on the less and the
more affected side) using the contralateral nuclei.
In the second stage of analysis we conducted
three independent multivariate analyses (one for each
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nucleus) to determine which clinical metrics sig-
nificantly predict midbrain nuclei volume when all
metrics are considered in the same statistical model.
For this second analysis we included the right and left
nuclei separately; therefore, a generalized estimating
equation model was used to account for correlated
right and left nuclei volumes within an individual.
We performed three models, one for each nucleus
(SN, STN, and RN), and each with a normal dis-
tribution, identity link function, and exchangeable
correlation structure specified. This equation mod-
eled nuclear volume as the sum of age, disease
duration, bradykinesia-rigidity severity, and tremor
severity.
Prior research has identified imaging differences
between the side of the brain contralateral to more
or less affected limbs of patients with PD [54, 55].
Therefore, we performed an exploratory analysis
separating midbrain nuclei contralateral to the More-
Affected versus Less-Affected sides. Paired t-tests
were used for within midbrain nuclei analysis and
Spearman rho correlation coefficients were calcu-
lated to assess the relationships between each of the
midbrain nuclei and clinical metrics.
Between PD and healthy control group differences
in SN, STN, and RN volumes were determined with
independent t-tests. For all analyses, two-tailed p val-
ues were used; those values of p ≤ 0.05 were defined
as significant. All statistical analyses were conducted
using SAS Enterprise Guide, version 7.11.
RESULTS
Participants
PD participants (Table 1) mean (±standard devi-
ation) disease duration was 4.1 (±2.1) years and
motor severity ranged from mild to moderate with
a mean MDS-UPDRS-III Off dopaminergic medica-
tions of 33.1 (±12.3). Off dopaminergic medications,
six participants were Hoehn and Yahr stage I (unilat-
eral involvement only), 22 were stage II (bilateral
involvement), and four were ≥stage III (bilateral
involvement with impairment of balance).
PD participants represent a mixture of motor sub-
types. Only one participant had a Tremor Subscore
of zero, but 11 had Tremor Subscores of less than
five and nine had Tremor Subscores of greater than
10. Using a Tremor/PIGD Subscore ratio of ≤0.90
[48], nine participants were classified as PIGD domi-
nant. When considering appendicular motor severity,
15 participants were more affected on the right side
and 17 were more affected on the left side.
Relationship of midbrain nuclei to PD motor
severity
Direct correlation analysis in the PD participants
demonstrated that a smaller SN volume correlated
with longer disease duration (r = –0.42, p = 0.004) and
higher (more severe) MDS-UPDRS-III (r = –0.42,
p = 0.016) (Figs. 2 and 3, Table 2), with a trend rela-
tionship with older age (r = –0.31, p = 0.08). There
was no association between STN or RN volumes and
disease duration, MDS-UPDRS-III, or age.
Next, we examined the association between
midbrain nuclei volumes and motor subscores
for bradykinesia/rigidity, PIGD, and tremor.
Smaller SN volume correlated with higher (more
severe) Bradykinesia-Rigidity Subscore (r = –0.47,
p = 0.007, Fig. 3), but not Tremor or PIGD Subscores
(Table 2). There was no relationship between STN




More-Affected Side Less-Affected Side
Mean (±SD) Range Mean (±SD) Range Mean (±SD) Range
N 32
Age, years 65.3 (±7.4) 52–79
Male:Female 15 : 17
Duration, years 4.0 (±2.1) 1–8
Hoehn and Yahr 2.2 (±0.7) 1–4
MDS-UPDRS-III 32.8 (±12.0) 6–62 14.0 (±4.1) 8–22 8.1 (±4.8) 0–18
Bradykinesia-Rigidity 18.5 (±7.7) 5–34 10.9 (±3.5) 6–18 6.8 (±4.2) 0–15
Subscore
Tremor Subscore 7.5 (±5.0) 0–16 5.0 (±3.4) 0–11 3.2 (±2.4) 0–8
PIGD Subscore 3.6 (±3.2) 0–15 – – – –
All motor scores are reported for the Off medication state. MDS-UPDRS-III, Movement disorders Society United
Parkinson’s disease Rating Scale part 3 motor exam; PIGD, postural instability/gait difficulty; SD, standard
deviation.
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Fig. 2. Disease Duration versus Midbrain Nuclei Volumes. Longer
duration of Parkinson’s disease diagnosis was only associated with
smaller volume of the substantia nigra, not the subthalamic nucleus
or the red nucleus. r, Spearman’s rho correlation coefficient.
We next performed three separate multivariate
analyses (one for each of the midbrain nuclei) using a
generalized estimating equation model to determine
the relationships between midbrain nuclei volumes
and clinical metrics when considered in the same
statistical model, thereby controlling for the possi-
ble confounding effects of age and disease duration
(Table 3). The Bradykinesia-Rigidity Subscore, dis-
ease duration, and age all predicted SN volume in the
same model (p < 0.0001). There were no significant
results for STN or RN volumes.
Four PD participants were ≥Hoehn and Yahr
stage III. They were older (mean ± SD 73.8 ± 5.5
versus 64.1 ± 6.9, p = 0.012), had lower MoCA
(20.3 ± 4.6 versus 26.8 ± 2.7, p = 0.001), and trended
toward worse MDS-UPDRS-III (42.5 ± 14.7 versus
31.5 ± 11.3, p = 0.083) compared to the 28 partic-
ipants with a Hoehn and Yahr stage I-II. Because
their older age, more severe cognitive impairment,
and early gait and balance problems could be indica-
tive of an alternative pathology, such as progressive
supranuclear palsy or co-morbid Alzheimer’s dis-
ease pathology, we removed them and repeated the
analysis. All relationships between midbrain nuclei
and clinical metrics remained similar in signifi-
cance and magnitude after these participants were
excluded.
Assessment of more- and less-affected midbrain
nuclei
We next explored the relationship between the
More- and Less-Affected hemi-body motor subscores
and contralateral midbrain nuclei volumes. The SN
contralateral to the More-Affected hemi-body was
smaller than that contralateral to the Less-Affected
hemi-body (p = 0.012). There were no significant
volumetric differences between the More- and Less-
Affected sides of the STN or RN.
Smaller SN volume contralateral to the Less-
Affected hemi-body correlated with higher total
MDS-UPDRS-III (r = –0.37, p = 0.038), but the SN
contralateral to the More-Affected hemibody did not
(p = 0.225). Similarly, smaller SN volumes contralat-
eral to the Less-Affected hemi-body correlated with
higher Bradykinesia-Rigidity Subscore (r = –0.41,
p = 0.019), but the SN contralateral to the More-
Affected hemibody only trended towards significance
(r = –0.35, p = 0.053; Fig. 4, Table 2). There were no
associations between hemi-body Tremor Subscores
and contralateral SN volumes.
Relationship of QSM and R2* to PD motor
severity
Recent studies have reported using the QSM and
R2* map as quantitative techniques to detect PD
associated midbrain nuclei changes [23, 31, 56]. We
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Fig. 3. Motor Severity versus Midbrain Nuclei Volumes. (A) Smaller substantia nigra volumes are associated with worsening of the total
Motor Score (MDS-UPDRS III) in Parkinson’s disease. (B) However, when the total motor score is broken down by symptom group, only
the Bradykinesia-Rigidity Subscore explained this relationship. There was no association with (C) postural instability/gait difficulty (PIGD)
or (D) Tremor severity. r, Spearman’s rho correlation coefficient.
Table 2
Correlations between midbrain nuclei volumes and Parkinson’s disease motor severity
Substantia Subthalamic Red
Nigra r (p) Nucleus r (p) Nucleus r (p)
Duration –0.49 (0.004) 0.14 (0.435) –0.07 (0.722)
Age –0.31 (0.082) 0.20 (0.276) 0.10 (0.593)
MDS-UPDRS-III total –0.42 (0.016) 0.29 (0.104) 0.25 (0.162)
Bradykinesia-Rigidity total –0.47 (0.007) 0.17 (0.339) 0.16 (0.373)
Tremor total 0.11 (0.579) 0.21 (0.282) 0.30 (0.116)
PIGD –0.31 (0.103) 0.32 (0.092) 0.22 (0.261)
MDS-UPDRS-III Less-Affected –0.37 (0.038) 0.33 (0.068) 0.31 (0.082)
Bradykinesia-Rigidity Less-Affected –0.41 (0.019) 0.29 (0.107) 0.24 (0.191)
Tremor Less-Affected –0.09 (0.635) 0.28 (0.125) 0.35 (0.053)
MDS-UPDRS-III More-Affected –0.22 (0.225) 0.16 (0.370) 0.24 (0.195)
Bradykinesia-Rigidity More-Affected –0.35 (0.053) 0.04 (0.850) 0.17 (0.363)
Tremor More-Affected 0.06 (0.765) 0.14 (0.448) 0.16 (0.398)
r, Spearmans’s rho correlation coefficient; MDS-UPDRS-III, Movement disorders Society
United Parkinson’s disease Rating Scale part 3 motor exam; PIGD, postural instability/gait
difficulty.
found lower SN R2*, higher SN QSM and higher
STN QSM each trended toward an association with
older age in PD participants (r = 0.33, p = 0.089;
r = 0.38, p = 0.054; r = 0.35, p = 0.078, respectively),
but neither QSM nor R2* in the SN, STN, or RN
was associated with disease duration, total MDS-
UPDRS-III, Bradykinesia-Rigidity, Tremor or PIGD
Subscores.
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Table 3
Results of the multivariate generalized estimating equation model
Nuclei Clinical Metric Change in Nuclei 95% Confidence
Volumes Interval
(Beta Coefficient) lower upper p value
Substantia Nigra
Bradykinesia-Rigidity Subscore –6.15 –9.81 –2.48 0.001
Tremor Subscale 0.72 –7.33 8.76 0.86
Duration –24.87 –35.74 –14.00 <0.0001
Age –4.16 –6.73 –1.58 0.0002
Subthalamic Nucleus
Bradykinesia-Rigidity Subscore –0.64 –2.69 1.40 0.54
Tremor Subscale 2.94 –1.18 7.07 0.16
Duration 3.42 –2.41 9.26 0.25
Age 1.70 –0.13 3.45 0.07
Red Nucleus
Bradykinesia-Rigidity Subscore –0.85 –2.96 1.27 0.43
Tremor Subscale –0.04 –4.00 3.92 0.98
Duration 0.16 –6.65 6.97 0.96
Age 0.79 –1.49 3.07 0.50
Fig. 4. Bradykinesia and Rigidity on the Less- and More-Affected
Sides. (A) The relationship between Bradykinesia-Rigidity Sub-
scale and SN volume was more pronounced on the Less-Affected
side compared to (B) the More-Affected side. r, Spearman’s rho
correlation coefficient.
Comparison between PD and healthy controls
The 32 PD and 8 healthy controls were matched
for age (65.3 ± 7.4 and 64.8 ± 6.9, respectively;
p = 0.847) and gender (male:female, 15:17 and 4:4,
respectively; p = 0.874). There were no between
group differences in SN, STN, or RN volumes. In
the healthy control group, smaller SN volume, but
not STN volume or RN volume, was significantly
associated with older age (r = –0.85, p = 0.007, Sup-
plementary Figure 1).
DISCUSSION
We used ultra-high field 7T MRI to segment
individual midbrain nuclei in vivo and determine
the differential association between nuclei volumes
and severity of specific PD motor manifestations.
Our results extend the clinicopathological relation-
ships described postmortem to mild-to-moderate PD
patients in vivo. Specifically, our data establish that
SN volumes tightly correlate with disease duration
and motor severity early in disease, which suggests
midbrain MRI quantification using QSM could be
an objective biomarker for disease severity in clini-
cal trials. Our data also confirm that the relationship
between SN volume and motor severity is specific to
bradykinesia and rigidity, but not tremor or PIGD.
Further, SN volumes decrease with age in both PD
patients and healthy control participants. Therefore,
ultra-high field MRI, particularly QSM, of the mid-
brain nuclei might be useful for studying the effect of
aging on PD.
Substantia nigra volume is associated with
bradykinesia-rigidity
Lewy body formation in the SN with subsequent
loss of dopaminergic neurons is the pathologic hall-
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mark of PD. Meticulous autopsy studies in the 1970s,
80s, and 90s uncovered a differential pattern of SN
neuronal cell loss between PD patients who were
akinetic-rigid dominant versus tremor dominant [4].
Specifically, these studies showed a negative correla-
tion between SN pars compacta neuronal cell counts,
disease duration [1, 2] and the severity of bradykine-
sia and rigidity, but not tremor [3, 5, 6]. These autopsy
studies are further supported by the clinical syndrome
manifest by patients with dopamine-receptor block-
ing drug-induced secondary parkinsonism, which
most commonly results in bradykinesia and rigid-
ity, but much less commonly asymmetric rest tremor
[57]. Animal studies also support the autopsy find-
ing that nigrostriatal dopaminergic deficiency is the
underlying cause for bradykinesia and rigidity, but
not tremor. For instance, in monkeys, lesions of the
midbrain mainly produce rigidity and only rarely
spontaneous sustained tremor [58, 59]. Similarly,
MPTP treated macaque monkeys mainly exhibit an
akinetic-rigid syndrome [60].
However, autopsy studies have critical limitations
because they typically include older patients with
more severe motor manifestations and longer dis-
ease duration and thus limit a comprehensive study
of these relationships in early disease. In Ma et al.,
the average age was 78 ± 6 years with an average
duration of 9.5 ± 4.2 years [1]. The average dura-
tion in Bernheimer et al was similarly 9.3 ± 0.9
years, with several patients having over 20 years of
symptoms [5]. In these late stages of disease, even
patients who present primarily with tremor will typi-
cally have since developed pronounced bradykinesia.
Furthermore, the few PD patients with short disease
duration (less than 5 years) prior to autopsy are usu-
ally older patients, who are more likely to present with
an akinetic-rigid syndrome [8]. Therefore, thorough
assessment of SN neuronal loss in earlier patients
with milder disease is only possible with in vivo tech-
niques, such as ultra-high field MRI. We used QSM at
7T to determine SN volume as a proxy for assessing
neuronal loss [61–64] and establish that SN volumes
are indeed related to milder bradykinesia-rigidity in
the first 10 years of disease.
Substantia nigra volume is not associated with
tremor or PIGD
The pathophysiology of PD tremor remains
unclear. Autopsy studies have also shown that
patients with tremor dominant PD have less severe
neuronal cell loss in the SN pars compacta, compared
to the akinetic-rigid patients [3, 4], and that the sever-
ity of neuronal loss is not related to the severity of
the tremor [4, 6]. It is generally thought that loss of
SN dopaminergic neurons is necessary, but not suf-
ficient, for the development of PD tremor [59, 65].
Indeed, our study is the first to confirm in vivo that
in mild to moderate PD grey matter loss within the
SN is not associated with tremor severity. This find-
ing has implications for using MRI quantification of
midbrain nuclei as a biomarker in PD clinical trials.
We also did not find SN volume to be asso-
ciated with PIGD severity. This is not surprising
given that both dopamine replacement and STN deep
brain stimulation generally fail to ameliorate these
symptoms sufficiently [66, 67]. While the underly-
ing pathophysiology specific to PIGD is unknown,
several mechanisms have been proposed including
cholinergic projections from the pedunculopontine
nucleus and cortical pathology [68, 69]. Our find-
ings are in line with autopsy studies which show that
PIGD patients have similar midbrain pathology as
non-PIGD [70]. However, the severity of PIGD in our
cohort was limited due to our focus on less severe
patients. Using a tremor/PIGD Subscore ratio only
nine participants were classified as PIGD dominant,
and four were Hoehn and Yahr stage III-IV. There-
fore it is possible that midbrain volumes, QSM or
R2* quantification could be associated with gait and
balance severity in more advanced patients [56].
Volumetrics of more and less affected nuclei
The motor symptoms of PD typically present
asymmetrically and continue to progress asymmet-
rically early in the disease. Few pathological studies
have compared the more versus the less affected brain
nuclei, because motor symptoms and brain pathology
become severe bilaterally later in the disease. Using
in vivo imaging in early disease duration patients we
were able to confirm that the SN contralateral to the
more affected hemi-body is smaller, possibly result-
ing from more severe atrophy. In addition, our data
suggest that nuclei volumes contralateral to the less
affected side have a stronger relationship with motor
severity. This is consistent with functional imaging
studies showing that in the first 6 years of disease
the dopamine uptake in the putamen contralateral to
the less affected hemi-body has fastest rate of decline
[55, 71]. Further, cross-sectional pathological stud-
ies show that in the SN pars compacta there is a 50
to 90% loss of dopamine neurons in the first 1 to 4
years after diagnosis with only marginal additional
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loss thereafter [2]. Our findings suggest that quan-
tification of midbrain nuclei volumes using 7T QSM
could detect very early changes in SN volume, which
could be applied to people with genetic risks for PD
to determine the rate of pre-clinical SN atrophy.
Substantia nigra volume is associated with age
Despite the clear SN volume association with PD
duration and severity, we did not find SN volumes
to be smaller in PD compared to the healthy adults.
Further, in both PD and healthy control participants,
smaller SN volume was associated with older age.
This suggests SN volume alone is not sufficient to
be a diagnostic biomarker for PD and that participant
age should always be considered when interpreting
MRI-based measures of midbrain structures.
Methodologic considerations
Our study uniquely leveraged QSM to identify
the boundaries of individual midbrain nuclei and
thus measure the volumes of these iron-containing
regions. Specifically, the SN has proven to be a chal-
lenging nucleus to delineate due to the border with
STN [72, 73]. Ultra-high field 7T MRI has shown
excellent T2*-weighted contrasts for depicting deep
gray nuclei, due to the superior iron sensitivity at high
field [9, 74]. However, T2*-weighted contrasts suf-
fer from blooming artifacts and hence are probematic
for volume quantification [39]. These blooming arti-
facts are particularly severe in the midbrain region
wherein iron-containing nuclei are situated in close
apposition and adjacent to air-tissue interfaces. A
major advantage of QSM is the attenuation of these
blooming artifacts through deconvolution [39, 42, 75,
76], which has been very useful in local tissue chara-
terization of diseases including hemorrhages [77],
inflammation of multiple sclerosis lesions [78, 79],
and iron within the SN pars compacta in PD [23, 25].
QSM results in high contrast between these iron-rich
nuclei and iron-sparse tissue [20, 56]. The combina-
tion of 7T MRI and QSM offers superior contrast for
midbrain nuclei, which enhanced the accuracy of the
segmentation performed in this study.
This study primarily focused on using QSM to
determine midbrain nuclei volumes, in contrast to
prior PD studies that focused on the utility of QSM
and R2* values to aid in differential diagnosis [23, 31,
80–82]. Prior 7T studies have also focused on visual
descriptions of nuclei [83], nuclei shape analysis, and
nuclei QSM values [31], but were not able to deter-
mine the nuclei volumes. Because iron quantity may
be variable in SN neurons in PD [11], it is difficult
to evaluate the number of surviving neurons using
QSM and R2* values directly. By contrast, we lever-
aged QSM to delineate the boundary between SN and
STN, allowing for accurate determination of these
midbrain nuclei volumes that are associated with PD
progression.
Another consideration of our technique is the use of
manual segmentation, which can be prone to human
error and bias. To minimize this potential limita-
tion we maintained a blind between the segmentation
team, who performed all pre-processing and segmen-
tation of de-identified scans, and the clinical analysis
team, who compiled all clinical metrics and statistical
analysis. Furthermore, 12 scans were independently
segmented by two raters, with high inter-rater agree-
ment. This is consistent with a studies comparing R2*
and QSM ultra-high field 7T MRI in PD patients,
which found using QSM images resulted in the high-
est interrater agreement in determining SN volumes
[28]. Finally, while multiple statistical tests were per-
formed in this study without explicit correction, our
future work will replicate these findings and further
delve into etiology and implications.
Future directions
A primary limitation of postmortem studies is
the inability to perform longitudinal assessment of
regional brain atrophy in individual patients. Conven-
tional MRI studies using cortical volumetric analysis
have provided significant insight into longitudinal
changes in regional atrophy associated with different
subtypes of dementia [84–86]. We have shown that
our in vivo technique with ultra-high field MRI can
be used for similar studies of midbrain nuclei in PD.
In addition, quantification of midbrain atrophy could
provide important insight into the development of PD
non-motor symptoms. For instance, dopamine neu-
ron loss has been suspected to drive the development
of certain cognitive impairments, such as executive
dysfunction. Indeed, longitudinal 7T MRI studies of
midbrain atrophy could provide significant insight
into the clinical correlates of pre-motor and early SN
dopamine loss in PD patients.
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